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Abstract
Background: The disabilities of the arm, shoulder and hand (DASH) questionnaire is a self-
administered region-specific outcome instrument developed as a measure of self-rated upper-
extremity disability and symptoms. The DASH consists mainly of a 30-item disability/symptom
scale, scored 0 (no disability) to 100. The main purpose of this study was to assess the longitudinal
construct validity of the DASH among patients undergoing surgery. The second purpose was to
quantify self-rated treatment effectiveness after surgery.
Methods: The longitudinal construct validity of the DASH was evaluated in 109 patients having
surgical treatment for a variety of upper-extremity conditions, by assessing preoperative-to-
postoperative (6–21 months) change in DASH score and calculating the effect size and standardized
response mean. The magnitude of score change was also analyzed in relation to patients' responses
to an item regarding self-perceived change in the status of the arm after surgery. Performance of
the DASH as a measure of treatment effectiveness was assessed after surgery for subacromial
impingement and carpal tunnel syndrome by calculating the effect size and standardized response
mean.
Results: Among the 109 patients, the mean (SD) DASH score preoperatively was 35 (22) and
postoperatively 24 (23) and the mean score change was 15 (13). The effect size was 0.7 and the
standardized response mean 1.2.
The mean change (95% confidence interval) in DASH score for the patients reporting the status of
the arm as "much better" or "much worse" after surgery was 19 (15–23) and for those reporting
it as "somewhat better" or "somewhat worse" was 10 (7–14) (p = 0.01). In measuring effectiveness
of arthroscopic acromioplasty the effect size was 0.9 and standardized response mean 0.5; for
carpal tunnel surgery the effect size was 0.7 and standardized response mean 1.0.
Conclusion: The DASH can detect and differentiate small and large changes of disability over time
after surgery in patients with upper-extremity musculoskeletal disorders. A 10-point difference in
mean DASH score may be considered as a minimal important change. The DASH can show
treatment effectiveness after surgery for subacromial impingement and carpal tunnel syndrome.
The effect size and standardized response mean may yield substantially differing results.
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Background
The disability of the arm, shoulder and hand (DASH)
questionnaire is an upper-extremity specific outcome
measure that was introduced by the American Academy of
Orthopedic Surgeons in collaboration with a number of
other organizations[1]. The rationale behind the use of
one outcome measure for different upper extremity disor-
ders is that the upper extremity is a functional unit[2]. In
this respect, the DASH would be suitable because of its
property of being mainly a measure of disability. In addi-
tion to decreasing the administrative burden associated
with using different disease-specific measures, one of the
main concepts behind developing the DASH was to facil-
itate comparisons among different upper-extremity condi-
tions in terms of health burden[1]. The DASH is now
available in several languages http://www.dash.iwh.on.ca,
and studies of reliability and validity have been published
for the original version[3] as well as for the German[4],
Italian[5], Spanish[6] and Swedish[7] versions. In addi-
tion, research studies regarding a French[8] and a
Dutch[9] version of the DASH have been published.
The DASH is being increasingly used in cross-sectional
studies. To enhance the use of the DASH in prospective
studies (such as assessment of effectiveness of different
treatment methods) further studies of the instrument's
ability to detect change over time would be helpful both
for interpretation of score changes and for sample size cal-
culations. Different aspects of an instrument's ability to
measure change have been highlighted including studying
changes over time for groups or individuals and compar-
ing groups at one occasion[10]. The analysis of score
change is commonly referred to as responsiveness[11–
15], but the term longitudinal construct validity has also
been used[16] and it has been advocated that responsive-
ness is a part of the validity analysis[15]. There is no con-
sensus on the nomenclature or the appropriate statistical
analysis and different suggestions have been
made[12,17–19]. To facilitate prospective research, longi-
tudinal studies of the instrument's ability to detect
changes and identify smaller and larger changes in health
status as perceived by the patient are needed.
We believe that the concept of detecting change over time
is part of the validity assessment and therefor may be
referred to as longitudinal construct validity. To date, we
have found only one published study concerning the lon-
gitudinal construct validity of the DASH in a variety of
orthopedic disorders of the upper extremity[3]. Consider-
ing the nature of the instrument, longitudinal construct
validity can be assessed among a group of patients with
different upper extremity disorders. In contrast, when
using the instrument in patients with a particular diagno-
sis the effectiveness of a specific treatment can be assessed.
To analyze treatment effectiveness the direction of change
becomes important, as opposed to analyzing longitudinal
construct validity, which concerns the ability to detect
change irrespective of whether the change is improvement
or worsening. Therefor it would be important to study the
longitudinal construct validity of the DASH as well as its
performance as a measure of treatment effectiveness.
The main purpose of this study was to assess the longitudi-
nal construct validity of the DASH among patients undergo-
ing surgery for a variety of upper extremity disorders. The
second purpose was to quantify self-rated treatment effec-
tiveness after surgery for subacromial impingement and
carpal tunnel syndrome when using the DASH. To ensure
reliability of the DASH in this study we also aimed to
determine the internal consistency of the scale in each
patient population studied.
Methods
The DASH questionnaire
The main part of the DASH is a 30-item disability/symp-
tom scale concerning the patient's health status during the
preceding week[20]. The items ask about the degree of dif-
ficulty in performing different physical activities because
of the arm, shoulder, or hand problem (21 items), the
severity of each of the symptoms of pain, activity-related
pain, tingling, weakness and stiffness (5 items), as well as
the problem's impact on social activities, work, sleep, and
self-image (4 items). Each item has five response options.
The scores for all items are then used to calculate a scale
score ranging from 0 (no disability) to 100 (most severe
disability). The score for the disability/symptom scale is
called the DASH score. In this study we used the Swedish
version of the DASH[7].
Patients
Patients with upper-extremity musculoskeletal conditions
planned for surgical treatment at an orthopedic depart-
ment were considered for inclusion in this study. Exclu-
sion criteria were age below 18 years, symptom duration
of less than 2 months, or inability to complete question-
naires due to cognitive impairment or language difficul-
ties. The DASH was completed preoperatively by 118
consecutive eligible patients[7]. Postoperatively, 9 (8%)
of the patients did not respond and the remaining 109
patients completed the DASH after a minimum followup
time of 6 months (Table 1). The 2 largest diagnostic
groups comprised patients who had undergone arthro-
scopic acromioplasty because of subacromial impinge-
ment and open carpal tunnel release because of carpal
tunnel syndrome. Complete followup could be obtained
for all patients in these 2 subgroups (Table 2).
The followup questionnaire also included an item regard-
ing change in health status after surgery. It inquired about
the status of the operated arm compared to its statusBMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/11
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preoperatively (5 response options: much better, some-
what better, unchanged, somewhat worse, much worse).
This item was accidentally missing in the initially mailed
questionnaires and was therefore only completed by the
last 83 participants.
Analyses
To assess one aspect of the reliability of the DASH scale
when used in this patient population, the internal consist-
ency was calculated using Cronbach alpha[21] for the
total population as well as for the subgroups with subac-
romial impingement and carpal tunnel syndrome. For
each of these populations, preoperative, postoperative
and change scores were computed for the DASH. These
scores were subjected to the one-sample Kolmogorov-
Smirnov test to assess normality of distribution. As a
measure of longitudinal construct validity, the effect size
and standardized response mean were calculated for the
DASH disability/symptom scale. The effect size was calcu-
lated as the mean difference between the baseline scores
and the followup scores (i.e., mean change scores)
divided by the standard deviation of the baseline scores.
The standardized response mean was calculated as the
mean change scores divided by the standard deviation of
the change scores.
As external criterion for change in health status after sur-
gery the item regarding how the patient rated the status of
the operated arm compared to its status preoperatively
was used. Because detecting both improvement and wors-
ening reflect longitudinal construct validity, the preopera-
tive-to-postoperative score differences were considered to
be in the same direction and the mean change in DASH
score and the 95% confidence interval (CI) was calculated
for the patients with the responses of "much better" or
"much worse" and those with the responses "somewhat
better" or "somewhat worse". The difference in the mean
change scores between these two groups was assessed with
the t-test.
For patients who reported that no change had occurred,
the mean change in DASH score and the 95% CI were cal-
culated (scores used in their actual direction).
The mean change in DASH score for the patients who did
not and those who did receive the transition item
regarding change in the status of the operated arm was
compared with the t-test.
To assess the size of health change after surgery for subac-
romial impingement and carpal tunnel syndrome (i.e.,
Table 1: Characteristics of all the responders and the two largest subgroups who completed the DASH before and after surgery, and 
the patients who did not respond after surgery (dropouts)
All responders Arthroscopic acromioplasty Carpal tunnel release Dropouts
n = 109 n = 25 n = 19 n = 9
Women (n) 63 12 17 3
Men (n) 46 13 2 6
Age: mean (range) years 52 (18–83) 54 (37–71) 52 (30–83) 56 (24–76)
Followup: mean (range) months 12 (6–21) 13 (9–21) 9 (6–11) -
Table 2: Patient diagnoses
Diagnostic Group Responders (n) Dropouts (n)
Subacromial impingement 25
Other shoulder disorders 3 1
Tennis elbow 3 1
Cubital tunnel syndrome 3
Finger/Hand tumor 4 1
Wrist/hand ganglion 7 1
Carpal tunnel syndrome 19
Dupuytren's disease 13 2
Tenosynovitis 10 1
Sequelae tendon laceration 4
Trapeziometacarpal arthritis 6
Other 12 2BMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/11
Page 4 of 6
(page number not for citation purposes)
treatment effectiveness), the change scores were used in
their actual direction and the effect size and standardized
response mean were calculated.
The relationship between the DASH change score and
time since surgery (months) was analyzed with the Pear-
son correlation coefficient (r).
Results
Reliability
The Cronbach alpha coefficient was above 0.9 for the
DASH disability/symptoms scale indicating good internal
consistency when used in this patient population (Table
3).
Longitudinal construct validity
Among the 109 participants the mean (SD) change in
DASH score was 15 (13) when all changes in scores
(improvement or worsening) were calculated as having
the same direction. The effect size was 0.7 and standard-
ized response mean 1.2 (Table 4).
Of the 83 patients who answered the transition item con-
cerning self-rated change in disability and symptoms after
surgery the mean change (95% CI) in DASH score in the
53 patients responding "much better" or "much worse"
was 19 (15–23) and in the 21 patients responding "some-
what better" or "somewhat worse" was 10 (7–14), (p =
0.01). For the 9 patients reporting no change in the status
of the arm after surgery (clinically stable group) the mean
change (95% CI) in DASH score was -0.3 (-3.6–3.0).
The mean change (95% CI) in DASH score for the patients
who did not receive the transition item was 16 (11–20)
and it was 15 (12–18) for the patients who responded to
the item (p = 0.9).
Comparison of measures of treatment effectiveness
For the group with subacromial impingement treated with
arthroscopic acromioplasty, the effect size was 0.9 and the
standardized response mean 0.5 (Table 4). For the group
with carpal tunnel syndrome treated with open carpal
tunnel release, the effect size was 0.7 and the standardized
response mean 1.0.
Correlation between score change and time since surgery
Among all 109 patients, no correlation was found
between the DASH change score and time since surgery (r
= 0.06, p = 0.56). The correlation was weak-to-moderate
but statistically non-significant among the patients treated
with arthroscopic acromioplasty (r = 0.29, p = 0.15) and
those treated with carpal tunnel release (r = 0.34, p =
0.16).
Discussion
The importance of monitoring the effectiveness of treat-
ment is well recognized and furthermore is the founda-
tion of evidence-based health care. For this purpose
Table 3: Internal consistency of the disabilities of the arm, shoulder and hand (DASH) questionnaire measured with the Cronbach alpha 
coefficient
Population DASH disability/symptoms scale
Preoperative Postoperative
Total population (n = 109) 0.97 0.98
Arthroscopic acromioplasty (n = 25) 0.92 0.97
Carpal tunnel release (n = 19) 0.96 0.98
Table 4: Results of the disabilities of the arm, shoulder and hand (DASH) disability/symptoms scale shown as scores, effect size (ES) and 
standardized response mean (SRM)
Population Preoperative* Postoperative* Change ES SRM
mean (SD) median mean (SD) median mean (SD) median
Total population (n = 109) 35 (22) 36 24 (23) 16 11 (17) 8 0.5 0.6
15 (13)† 12† 0.7 1.2
Arthroscopic acromioplasty (n = 25) 43 (13) 45 32 (25) 24 11 (23) 6 0.9 0.5
Carpal tunnel release (n = 19) 41 (20) 40 28 (26) 15 13 (14) 10 0.7 1.0
Dropouts (n = 9) 24 (18) 28
*Higher score (0–100) indicates greater disability †All changes in scores (improvement or worsening) calculated as having the same direction (to 
assess longitudinal validity of the DASH as opposed to assessing treatment effectiveness)BMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/11
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instruments that have the ability to detect changes and
can differentiate a small difference from a large difference
are needed. In a previous study, the DASH score change
was reported for 172 patients with different upper extrem-
ity disorders (such as shoulder arthritis and carpal tunnel
syndrome). The mean change between baseline and fol-
lowup scores 12 weeks after treatment was 13 (SD 17), the
effect size was 0.6 and the standardized response mean
was 0.8[3]. The changes were also shown for patients rat-
ing their problem as better (mean score change 17, effect
size 0.75, standardized response mean 1.1) and patients
rating their function as better (mean score change 20,
effect size 0.8, standardized response mean 1.2). Also,
based on the results of the present study, it appears that
the DASH has the ability to detect changes on group level
corresponding to the patients' perception after surgery in
a variety of upper extremity disorders. A significant differ-
ence in DASH scores between patients responding "much
better/worse" and "somewhat better/worse" was found
showing the instruments ability to discriminate between
these degrees of change. A mean score change of 19 indi-
cated a change in disability rated as "much better/worse"
and a mean score change of 10 as "somewhat better/
worse". It has been suggested that the score change rated
as "somewhat changed" could be defined as the limit for
minimal important change[18]. This information could
then be used for power calculations when planning pro-
spective studies. In a recent study a DASH score change of
15 has been suggested to discriminate between improved
and unimproved patients[3]. This was based on the
patients' responses to a question about "being able to
cope with the problem and do what you would like to
do", with a response change from "not being able to cope"
before treatment to "being able to cope" at followup con-
sidered as criterion for improvement[3]. However, we
believe that a change in disability can be important even
if the patients are not able to do all what they want to do
or, at a particular time, not being able to cope with the
problem. Future investigations are needed to determine
whether the DASH is sensitive to milder degrees of impact
other than that of surgery.
The difference noted in the group stating no change
(mean score change -0.3) can be seen as the difference
that occurred by chance and was similar to the score
change previously reported[3,7]. A difference of this size
should not be considered as a real change of upper
extremity disability.
In the analysis of health transition only the last 83
patients were included because the item was accidentally
missing in the initially mailed questionnaires. The mean
change in DASH score did not significantly differ between
the patients who did not receive and those who
responded to the transition item suggesting that it is
unlikely the missing item could have substantially influ-
enced the results.
We chose to use self-rated change of health status in the
operated arm as external criterion in order to ensure that
it did not capture global health changes not related to the
upper extremities.
The minimum followup time in the present study was 6
months and the latest response was received 21 months
after surgery. The minimum followup time was chosen as
it was expected to be sufficient to show improvement after
surgery in most disorders. As shown in the correlation
analysis time since surgery had, within this followup
period, only weak-to-moderate but statistically non-sig-
nificant association with the change in DASH scores after
arthroscopic acromioplasty and carpal tunnel release.
However, the difference in followup time is a limitation
that can have implication, particularly when interpreting
the size of change in DASH score for the assessment of
treatment effectiveness. The possible implication of
response shift also needs to be evaluated in future studies.
In this study the DASH demonstrated high Cronbach
alpha values, indicating an excellent internal consistency
that is adequate for group as well as for individual
comparisons[22]. These results support the use of the
DASH to measure changes in upper extremity function
also on an individual level. However, for individual
patient assessment with the DASH the magnitude of score
change has to be studied on individual level[17]. It is
important to note that in the present study only longitu-
dinal construct validity on group level has been analyzed.
The treatment effectiveness calculations showed that for
arthroscopic acromioplasty the effect size was larger than
the standardized response mean, while for carpal tunnel
release the opposite was shown. This illustrates the diffi-
culties with interpretation of such calculations when only
one of the analyses is presented. Since the effect size is
dependent on the homogeneity of the group preopera-
tively and the standardized response mean is dependent
on the homogeneity of the change of disability, these cal-
culations will by nature differ in almost any group. Both
calculation methods are common; however, little has
been discussed about the limitations associated with these
analyses, though it has been highlighted[15,18]. The use
of the DASH in other populations of similar diagnostic
groups and interventions is needed to show the degree of
consistency in the estimates of treatment effectiveness.
Conclusions
The DASH can detect and differentiate small and large
changes in disability over time after surgery in patients
with upper extremity musculoskeletal disorders. A 10-Publish with BioMed Central    and   every 
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point difference in mean DASH score might be considered
as a minimal important change. The DASH can show self-
rated treatment effectiveness after surgery for carpal tun-
nel syndrome and subacromial impingement. The effect
size and standardized response mean (commonly used
indices of the magnitude of health change measured by
questionnaires) may yield substantially differing results.
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